C
에스티큐브
052020KOSDAQ51.3 / 100
Reference Date: 2026-09-08
Financial Score16.0 / 40
News Sentiment21.3 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 5.2% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
STCube operates in biopharmaceuticals and cosmetics distribution, with its innovative immunotherapy drug 'Nelmastobart' showing promising clinical results. The company's own brand 'Scenearth' is expanding globally, while industrial lens module distribution contributes significantly to revenue.
Number of Employees
16people
Average Salary
66.0M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
7.82Industry Average 1.200.0Point
6.5x industry avg (risky)
ROE
-26.20Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
19.56Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20254.0 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲27.8% (2-year basis)
Operating Profit Growth Rate
1.0 / 3
Avg ▲4.7% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -38.6% (improving, 3yr)
Detailed News Sentiment
1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85
- Positive에스티큐브, WCLC서 넬마스토바트 비소세포폐암 임상 2상 초기 결과 ...
에스티큐브의 넬마스토바트 임상 2상 초기 결과 발표로 인해 비소세포폐암 치료제 개발에 대한 긍정적 기대감 증가.
Detailed Momentum
52-week position1.0Point
Near 52w low (11%, downtrend)
Current 8,300Won52-week high 22,10052-week low 6,490
1-month return2.0Point
1m -5.25% (slight drop)
Volume trend1.0Point
Volume decreasing
Detailed Disclosure
1 totalPositive 0Neutral 1Negative 0
- Neutral반기보고서 (2026.06)2026-08-14